EUVIMEDEUVIMED entdecken
Crossref

Association of FISH cytogenetic risk and baseline PET/CT findings with early treatment response and disease progression in patients with newly diagnosed multiple myeloma

Mustafa Kemal Yeniay, Özlem Anlaş, Feyza Altunbaş Yalabık, Zehra Narlı Özdemir, Oktay Bilgir

Journal of Current Hematology & Oncology Research · 13.11.2026 · 4 (4) · 159-165

DOI: 10.51271/jchor-0101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 13.11.2026. Verfasst von Mustafa Kemal Yeniay und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the association of fluorescence in situ hybridization (FISH)-defined cytogenetic risk and baseline positron emission tomography/computed tomography (PET/CT) findings with early treatment response and early disease progression in patients with newly diagnosed multiple myeloma (MM).

Methods

Seventy patients with newly diagnosed MM were included in this retrospective study. Clinical characteristics, International Staging System (ISS) and Revised ISS (R-ISS) stage, lactate dehydrogenase (LDH) level, FISH-defined cytogenetic risk, and baseline PET/CT parameters, including the number of focal lesions, maximum standardized uptake value (SUV max), extramedullary disease, bone marrow involvement, and metabolic risk group, were recorded. Treatment responses after the second and fourth cycles were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory associations with PFS were assessed using Cox proportional hazards regression.

Results

According to baseline PET/CT, 81.4% of patients were classified as having a metabolically high-risk disease. Compared with the metabolically low-risk group, patients in the metabolically high-risk group achieved significantly higher rates of very good partial response (VGPR) after the second cycle (49.1% vs. 15.4%, p=0.032) and ≥VGPR after the fourth cycle (64.9% vs. 23.1%, p=0.011). However, progression rates did not differ significantly between the two groups (p=0.675). Although response rates and progression frequency were numerically higher in the FISH high-risk group, these differences did not reach statistical significance. Kaplan–Meier analysis demonstrated longer PFS in female patients (p=0.001); ≥VGPR after the fourth cycle was not significantly associated with PFS (p=0.116). In the multivariable Cox model (13 PFS events), female sex remained significantly associated with PFS (HR=0.067, 95% CI 0.008–0.569, p=0.013), although the estimate was unstable because of the very limited number of events. The 1-year PFS and OS rates were 86% and 92%, respectively.

Conclusion

In this exploratory cohort, the study-specific PET/CT metabolic risk classification was associated with deeper early treatment responses but not with short-term disease progression. FISH-defined cytogenetic risk was not significantly associated with early response or progression. Given the short follow-up duration, limited number of events, and lack of external validation of the metabolic risk classification, these findings should be considered preliminary and do not establish the independent prognostic value of PET/CT or FISH-defined risk.

Zitieren

APA

Yeniay, M. K., Anlaş, Ö., Yalabık, F. A., Özdemir, Z. N., & Bilgir, O. (2026). Association of FISH cytogenetic risk and baseline PET/CT findings with early treatment response and disease progression in patients with newly diagnosed multiple myeloma. Journal of Current Hematology & Oncology Research, 4(4), 159-165. https://doi.org/10.51271/jchor-0101

Vancouver

Yeniay MK, Anlaş Ö, Yalabık FA, Özdemir ZN, Bilgir O. Association of FISH cytogenetic risk and baseline PET/CT findings with early treatment response and disease progression in patients with newly diagnosed multiple myeloma. Journal of Current Hematology & Oncology Research. 2026;4(4):159-165. doi:10.51271/jchor-0101

BibTeX
@article{Yeniay2026,
  author = {Yeniay, Mustafa Kemal and Anlaş, Özlem and Yalabık, Feyza Altunbaş and Özdemir, Zehra Narlı and Bilgir, Oktay},
  title = {Association of FISH cytogenetic risk and baseline PET/CT findings with early treatment response and disease progression in patients with newly diagnosed multiple myeloma},
  journal = {Journal of Current Hematology & Oncology Research},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {159--165},
  doi = {10.51271/jchor-0101}
}
Kostenlos starten →